Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 38Kidney Neoplasms 20Melanoma 14Neoplasm Metastasis 13Prostatic Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Uterine Cervical Neoplasms 4Colorectal Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Merkel Cell 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Vaginal Neoplasms 1Turcot syndrome 1Skin Neoplasms 1Penile Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Multiple Myeloma 1Microsatellite Instability 1Mesothelioma, Malignant 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Interleukin-2 × Genitourinary × Clear all
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡